Related Experiment Video
Updated: Mar 8, 2026

05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
4.6K
Acute PD: Evidence, Guidelines, and Controversies☆
Daniela Ponce1, Andre Balbi1, Brett Cullis2
1Department of Medicine, Botucatu School of Medicine, Sao Paulo, Brazil.
Seminars in Nephrology
|February 4, 2017
Summary
Peritoneal dialysis (PD) offers a safe and cost-effective option for acute kidney injury (AKI), especially in developing nations. Advances in technology and new guidelines are improving its use for critically ill patients.
Area of Science:
- Nephrology
- Critical Care Medicine
Background:
- Peritoneal dialysis (PD) was once a common treatment for acute kidney injury (AKI) but declined with the rise of extracorporeal therapies.
- Renewed interest in PD for AKI is driven by its cost-effectiveness and minimal infrastructure needs, particularly in developing countries.
Purpose of the Study:
- To review the technical advancements, clinical advantages, and limitations of using PD for AKI treatment.
- To discuss recent literature and the impact of new guidelines on PD for AKI.
Main Methods:
- Review of recent literature on clinical experiences with PD in AKI patients.
- Discussion of technical aspects, including cyclers, flexible catheters, and high-volume fluid use.
- Consideration of challenges in developing countries, such as research infrastructure limitations.
Main Results:
- PD is a feasible and safe alternative for AKI, with improved outcomes due to technological advancements.
- Studies from developing countries demonstrate successful PD treatment in critically ill patients.
- New guidelines aim to standardize PD indications, dosing, and management of complications in AKI.
Conclusions:
- Peritoneal dialysis is a viable and increasingly utilized option for managing acute kidney injury, particularly where resources are limited.
- Ongoing research and updated guidelines are crucial for optimizing PD therapy in AKI and addressing evidence gaps.
Related Concept Videos
Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Neural Regulation
43.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.9K
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K

